ASX: RKT







Investor Presentation

September 2024

Disclaimer



Summary

This presentation has been prepared by RocketDNA Limited. ("RocketDNA" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in RocketDNA, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of RocketDNA and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. RocketDNA is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of RocketDNA securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of RocketDNA its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and RocketDNA does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of RocketDNA to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which RocketDNA will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, RocketDNA and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Not Financial or Product Advice

This presentation is for information purposes only and is not a prospectus, product disclosure statement or other offer document under Australian law or the law of any other jurisdiction. This document is not a financial product or investment advice, or a recommendation to acquire securities in RocketDNA Limited, nor is it legal or tax advice. You are solely responsible for seeking independent and professional advice in relation to the information contained in this presentation and any action taken on the basis of that information. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate to their jurisdiction.

Financial Data

All dollar values are in Australian dollars (A\$) unless stated otherwise.

Past performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. The historical information in this presentation is, or is based upon, information that has been released to the Australian Securities Exchange (ASX). This presentation should be read in conjunction with RocketDNA Limited's other periodic and continuous disclosure announcements which are available at www.asx.com.au.

Future performance

The presentation includes forward-looking statements regarding future events and the future financial performance of RocketDNA Limited. Forward looking words such as "expect", "should", "could", "may", "predict", "plan", "will", "believe", "forecast", "estimate", "target" or other similar expressions are intended to identify forward-looking statements. Any forward looking statements included in this document involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, RocketDNA Limited and its officers, employees, agents or associates. In particular, factors such as variable climatic conditions and regulatory decisions and processes may affect the future operating and financial performance of RocketDNA Limited. This may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The Information also assumes the success RocketDNA Limited's business strategies. The success of the strategies is subject to uncertainties and contingencies beyond control, and no assurance can be given that the anticipated benefits from the strategies will be realised in the periods for which forecasts have been prepared or otherwise. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements. RocketDNA Limited is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. The forward-looking statements in this presentation speak only as at the date of this presentation.

No advertisement

This document does not constitute an advertisement for an offer or proposed offer of securities. It is not intended to induce any person to engage in, or refrain from engaging in, any transaction.

Disclaimer

Except as required by law, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, reliability or correctness of the Information, opinions and conclusions, or as to the reasonableness of any assumption contained in this presentation. By receiving this presentation and to the extent permitted by law, you release RocketDNA Limited and its officers, employees, agents and associates from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising as a result of the reliance by you or any other person on anything contained in or omitted from this presentation. To the maximum extent permitted by law, RocketDNA Limited and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in or failure to participate in the Offer and the information in the presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, RocketDNA Limited and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.



We leverage AI and Autonomous Drones to provide Mission Critical Data Services for Enterprise Customers.

BARS Certified

Highest Safety Recognition

RocketDNA has been verified in both South Africa and Australia against the BARS standard - one of the highest commitments to safety in the contracted aviation world.

BVLOS Approved

Enabling Long-Range Operations

With approval from the local Civil Aviation & Safety Authorities, we are able to execute long-range Beyond Visual Line of Sight missions, unlocking cost efficiencies.

Remote Operations

Our Multiplier Effect

Deploying a swarm of autonomous xBot® units enables our data products at a global scale. Missions are conducted 24/7 from one of our worldwide remote operation centres.

Al-Enabled

Faster Geospatial Insight

A growing segment of our data products and insights are powered by Al tools, allowing us to process, quantify and report faster than previous manual calculations

Investment Highlights

Why RocketDNA (ASX: RKT)






- Unique market validated business with high barriers to entry
- Proprietary Al-centric solution with high commercial value-in-use
- Visible and growing global addressable customer markets
- Secured complex and hard to obtain aviation regulatory authorisations, including BVLOS, and Remote Operations
- Scalable operation with demonstrated recurring revenue model



Company Snapshot

Enterprise Value (A\$)			
Market cap ¹	Share price \$0.014 at 12 September 2024	\$9.19M	
Cash ²	As at 30 June 2024	\$1.44M	
Debt ²	As at 30 June 2024	-	
Enterprise value	12 September 2024	\$7.75M	

Key Operating Metrics (A\$) (December Financial Year-End)				
Revenue FY 2023	End Dec 2023	\$6.137M	+7% on FY22	
Revenue H1 2024 ³	End Jun 2024	\$3.476M	+9% on H2 FY23	
ARR ⁴	End Jun 2024	\$2.727M	-4% compared to end FY23	



¹ 656,114,841 ordinary shares outstanding at the date, including those in voluntary escrow

² Excluding shareholder loans, credit cards, motor vehicle and equipment leasing

³ Unaudited

⁴ Annual Recurring Revenue (ARR), Total Contract Value (TCV), see 'ARR | TCV' slide for details.

Our Customer Base

ROCKET DNA 🔾

Growing tier-1 and tier-2 customer base; trusted and used by these companies













































Our xBot® Platform


Automating Drone Data Capture on a Global Scale





- Locally Manufactured
- Up to 8km Range/ 40-minute flight time
- Redundant Starlink/ 5G Connection for Worldwide operational reach












Automating Front-line Surveillance & Perimeter Monitoring




- Identify and qualify all/any threat
- Share live feed and location with ground team
- Coordinate with on-site ground team to identified suspect location





FINANCIAL HIGHLIGHTS



Quarterly Results - Highlights



Q2 FY2024 (June) and half year 2024 ¹

Operating Cash Flow Improvement and Autonomous system rolling in H1 2024; strong pipeline

ARR AND TCV

- ARR \$2.7m
 Down 10% on prior
 quarter (Q1 FY2024) and
 up 3% on Q2 FY2023
- TCV \$4.1m down 14% on prior quarter (Q1 FY2024) and down 6% on Q2 FY2023

TCV is impacted by ongoing existing contract depletion (run-off)

Revenue & Cash Receipts

- Revenue Q2 \$1.744m
 up 1% on the prior
 quarter and up 18% on
 Q2 FY23; H1 2024 up
 9% on H2 2023
- Cash Receipts \$1.9m down 4% on prior quarter and up 11% on Q2 FY2023; H1 2024 up 11% on H2 2023
- Contracted revenue accounted for 41% of total revenue (based on Q2 FY2024)

Operating Cash flow

- Net cash used in operating activities in H1 2024 significantly improved over H2 2023, down 56% at \$296k, down
 - improvement is on the back of growing cash receipts and good cost management

Key Initiatives

- Capital raise completed raising \$1.065m in
 December 2023
 - to fund the autonomous drone business
 - raised from institutional and sophisticated investors including a well-regarded family office

RocketDNA CEO Christopher Clark said: "Our second quarter 2024 saw strong pipeline activity, which resulted in a boost to project revenues for our existing business and brought two important xBot® trials to fruition – one in tier 1 mining and one in public infrastructure.

I am also pleased with our financial progress, in particular with operating cash flows, which, excluding a one-off tax payment, moved closer to operating cash flow breakeven"




Annual revenue growth¹

Growing track record

24% of Total Revenue is generated in Australia (based on H1 2024)

41% of Total Revenue is multi-year contracted revenue (based on H1 2024)



Revenue and Cash Receipts¹






Cash Receipts From Customers, \$m



Revenue by Type, \$m¹





Revenue derived from contracts (linking to ARR) was 41%

Of total Revenue in June Quarter 2024

Revenue types

Revenue one-off

Revenue which does not meet the above definitions (these are typically one-off short projects)

Revenue likely to re-occur


Revenue which management have a reasonable expectation will reoccur in the future either because it has been historically demonstrated to re-occur or because we hold rolling short term purchase orders or legal contracts which are less than 12 months in original length

Revenue legally contracted and recurring

Revenue from legal contracts with minimum original terms of 12 months, subject to normal termination provisions per each contract. The TCV and ARR measures contain only this type of contract.

ROCKET DNA 🔾

Net Cash Used in Operating Activities¹






Net cash used in operating activities in June quarter included \$158k of payments relating to prior year income tax in Ghana.



The Company continues to reduce cash used in operating activities on the back of growing cash receipts and good cost management.







\$1.000

Jun Quarter 2023



\$0.500

\$0.000

Contracted recurring revenue accounted for 41% of total revenue in Q2 FY2024

Dec Quarter 2023

Sept Quarter 2023



Whilst ARR has been impacted by the termination of the 3-year Calidus contract, this has been replaced by a month-to-month arrangement.

Jun Quarter 2024

Mar Quarter 2024

Jun Quarter 2023

Sept Quarter 2023

Dec Quarter 2023

Mar Quarter 2024

Jun Quarter 2024



STRATEGY,
MARKET &
GROWTH
PATHWAY



Market Opportunity

By 2043, total drone flights in

Australia are expected to reach 60

million per year¹

The Mining Industry will operate over 500,000 drone flights¹

Over 300,000 flights
will be used to assist
frontline Policing
efforts¹




Chart: Total Number of annual drone flights (millions): 2023 – 20431

¹ Source: Scyne Advisory: Sizing the future drone and advanced air mobility market in Australia (www.scyne.com)

Growth Pathway

Our focus for FY2024



BUSINESS MODEL



- Multi-Year Contracts
 - Conversion of current customers into long-term agreements
- Al & GIS Data Products Sales
 - Immediate productivity and cost benefit for mining customers
- Automated xBot® Data Capture
 - We continue to receive strong demand across the continent for ad-hoc projects

OP. & FINANCIAL EFFICIENCY



- Initiatives that bring us closer to break-even
- Continue to contain & reduce corporate overheads, fees & consulting
- Improve operational process flows (data capture and processing)
- Utilise debt-sourced funding for operational 'growth' purposes, such as scaling new contracts

CUSTOMER GROWTH



- Tier 1 Mining Strategy
- Tier 2 & 3 Mining Strategy
- New Sectors: Public Safety & Critical Asset Surveillance

ACQUISITIONS



Pursue complementary opportunities that add value to our business and help us build further economies of scale





Thank You

Contact

Chris Clark

Managing Director & CEO contact@rocketdna.com



